引用本文:张 艳,沈建军,沈 琦,陈 若,张红雁.胃癌术后同步放化疗与单纯化疗疗效及毒副反应的Meta分析[J].中国临床新医学,2019,12(4):396-401.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 47次   下载 39 本文二维码信息
码上扫一扫!
分享到: 微信 更多
胃癌术后同步放化疗与单纯化疗疗效及毒副反应的Meta分析
张 艳,沈建军,沈 琦,陈 若,张红雁
230001 合肥,安徽医科大学附属省立医院肿瘤放疗科
摘要:
[摘要] 目的 通过评价胃癌术后同步放化疗与单纯化疗的疗效与毒副反应,确定胃癌术后更佳的治疗方案。方法 2名研究者分别检索Pubmed,EMBASE和Cochrane library及中国知网、万方、维普等文献检索库,时间为建库到2018-07。共纳入21篇随机对照试验,共计2 299例研究对象,主要结局指标为3年、5年总生存期(overall survival,OS),次要结局指标为3年、5年无疾病进展期(disease-free survival,DFS)和毒性反应。研究纳入P值、RR风险比、95%置信区间(95%CI)以及发表偏倚。结果 术后同步放化疗较单纯化疗提高了3年及5年OS(RR=0.737,95%CI:0.664~0.819,P=0.000;RR=0.818,95%CI:0.718~0.932,P=0.003);3年及5年DFS(RR=0.770,95%CI:0.686~0.864,P=0.000;RR=0.772,95%CI:0.620~0.962,P=0.021),但增加了Ⅲ度及以上的消化道系统及血液系统的毒副反应(RR=1.455,95%CI:1.134~1.868,P=0.003;RR=1.208,95%CI:1.036~1.410,P=0.016)。结论 胃癌术后同步放化疗可延长OS及DFS,但增加了治疗相关毒副反应。
关键词:  胃肿瘤  放射治疗  化疗
DOI:10.3969/j.issn.1674-3806.2019.04.11
分类号:R 735.2
基金项目:安徽省自然科学基金项目(编号:1708085QH193)
A Meta analysis of the efficacy and side effects of concurrent chemoradiotherapy and chemotherapy after gastric cancer surgery
ZHANG Yan, SHEN Jian-Jun, SHEN Qi, et al.
Department of Oncological Radiotherapy, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, China
Abstract:
[Abstract] Objective To evaluate the curative effect and toxic and side effects between postoperative chemo-radiotherapy(ChRT) and chemotherapy(Ch) to detemine the better treatment options. Methods Two investigators independently searched Pubmed, EMBASE, Cochrane library, CNKI,CQVIP and Wangfang Database(data span time from the time of establishing database to July 2018) for randomized controlled trials(RCTs) comparing postoperative ChRT with Ch. Twenty one RCTs comparing postoperative ChRT with Ch(n=2 299) were included and 2 299 patients were included. The primary outcomes were 3- and 5-year overall survival(OS), while the secondary outcomes were 3- and 5- year disease-free survival(DFS) and toxicity. P value(P), risk ratio(RR) and 95% confidence intervals(CIs) were calculated, and bias was analyzed. Results Postoperative ChRT improved 3- and 5-year OS and 3- and 5- DFS compared to postoperative Ch(RR=0.737, 95%CI: 0.664~0.819, P=0.000; RR=0.818, 95%CI: 0.718~0.932, P=0.003; RR=0.770, 95%CI: 0.686~0.864, P=0.000; RR=0.772, 95%CI: 0.620~0.962, P=0.021), but also increased the digestive system toxicity and hematological system toxicity(RR=1.455, 95%CI: 1.134~1.868, P=0.003; RR=1.208, 95%CI: 1.036~1.410, P=0.016). Conclusion ChRT improves 3- and 5-year OS and 3- and 5-year DFS as compared to Ch alone, but also increases toxicities.
Key words:  Gastric cancer  Radiotherapy  Chemotherapy